Loading

Commentary Open Access
Volume 4 | Issue 1 | DOI: https://doi.org/10.46439/signaling.4.098

FRα-targeted PDT in ovarian cancer: beyond cytotoxicity, an immunomodulatory therapy

  • 1Univ.Lille, Inserm, CHU Lille, U1366-CRCLille – Laboratoire OncoThAI, 59000 Lille, France
  • 2Department of Gynecological Surgery, Lille University Hospital, 1 Avenue Oscar Lambret, Lille F-59000, France; Lille University Hospital, University of Lille, Lille F-59000, France
  • #Equally First Authors
  • Equally Last Authors
+ Affiliations - Affiliations

Corresponding Author

Nadira Delhem, nadira.delhem@univ-lille.fr

Received Date: February 17, 2026

Accepted Date: April 29, 2026

Abstract

In our recent published study entitled “Targeted Photodynamic Therapy using a Vectorized Photosensitizer coupled to a Folic Acid Analog induces Ovarian Tumor Cell Death and inhibits IL-6-mediated Inflammation”, we explore the effect of a new approach for the treatment of ovarian cancer. We found that photosensitizer coupled to an analog of folic acid (PSFAA) selectively accumulates in ovarian cancer cells and, upon light activation, induces an efficient photodynamic cytotoxicity. Moreover, we demonstrate that FRα-targeted PDT induces an inhibition of the pro-tumoral and immunosuppressive IL-6 cytokine secretion. The results support that FRα-targeted PDT not only eradicates residual ovarian tumor cells but could also modulate the immune microenvironment. In this commentary, we introduce more in-depth ovarian cancer immune background, summarize key findings of the published work, and discuss emerging questions and future research directions, focusing on FRα PDT-induced immune re-activation and its potential to re-sensitize ovarian cancer to immunotherapies.

Author Information X